Ebola – Democratic Republic of the Congo
23: Situation report on the Ebola outbreak in North Kivu
8 January 2019 [Excerpts]
On 24 November 2018, MoH announced the launch of a randomized control trial for Ebola therapeutics. This first-ever multi-drug randomized control trial within an outbreak setting, is an important step towards finding an effective evidence-based treatment for Ebola. The trial is coordinated by WHO and led and sponsored by the Democratic Republic of the Congo’s National Institute for Biomedical Research (INRB) which is the principal investigator. The trial has begun in the Alliance for International Medical Action (ALIMA) ETC in Beni, where patients are enrolled in the study after obtaining voluntary informed consent. MSF treatment centres are also preparing to launch the trial at their sites in the near future.
Until other ETCs are ready to launch the trial, they will continue to provide therapeutics under the Monitored Emergency Use of Unregistered Interventions (MEURI) (compassionate use) protocol, in collaboration with the MoH and the INRB, together with supportive care measures. WHO continues to provide technical clinical expertise on-site at all treatment centres. UNICEF is providing nutritional treatment and psychological support for all hospitalized patients.
As of 6 January 2019, a total of 151 patients are hospitalized in ETCs, of which 29 are confirmed cases, receiving compassionate therapy.
As of 4 January 2019, Katwa ETC has been opened and admitted three suspected cases.
…Implementation of ring vaccination protocol
As of 6 January 2019, a total of 56,509 individuals have been vaccinated since the start of the outbreak.